Cantuzumab
This product is a humanized monoclonal antibody targeting the CanAg antigen, a tumor-associated carbohydrate antigen highly expressed in gastrointestinal and pancreatic cancers. It specifically serves as the antibody backbone for experimental antibody–drug conjugates (ADCs).
Key Features and Benefits
-
Humanized Antibody: Minimizes immunogenicity for therapeutic applications.
-
CanAg Targeting: Binds selectively to the CanAg tumor-associated antigen.
-
ADC Backbone: Serves as the targeting component for drug conjugates.
-
Therapeutic Potential: Investigated in multiple cancer types, including gastrointestinal and pancreatic tumors.
-
High Specificity: Reduces off-target interactions compared to non-targeted therapies.
Applications
-
Oncology Research: Explores CanAg-targeted therapy for gastrointestinal and pancreatic cancers.
-
ADC Development: Used as a backbone for experimental drug conjugates.
-
Drug Discovery: Supports design of targeted cancer therapeutics.
-
Translational Medicine: Provides a model for tumor-associated antigen targeting.
Storage and Handling
-
Storage: Store at –80 °C in sealed vials for long-term stability.
-
Handling: Thaw gently on ice; avoid repeated freeze–thaw cycles.
This product is a humanized monoclonal antibody that specifically targets CanAg, specifically providing a foundation for ADC development and targeted cancer research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
